Clade Ib: First deadly mpox virus strain detected in UK after patient returns from Africa
The UK has detected its first deadly mpox virus strain.
The UK Health Security Agency (UKHSA) said the Clade Ib was detected in London from an infected individual who recently returned from Africa on October 21.
While the risk to the public remains low, the UKHSA is tracing fewer than 10 close contacts, primarily household members, and monitoring the situation closely.
Upon returning, the patient developed flu-like symptoms a day later, followed by a worsening rash by October 24. They sought medical assistance at a London emergency department on October 27, where they were tested and instructed to self-isolate while awaiting results. The patient has since been transferred to the Royal Free Hospital’s high consequence infectious diseases unit for treatment.


UKHSA Chief Medical Adviser Professor Susan Hopkins said: “It is thanks to our surveillance that we have been able to detect this virus. This is the first time we have detected this Clade of mpox in the UK, though other cases have been confirmed abroad.”
While mpox transmission typically requires close physical contact, the virus can spread through direct contact with a rash, bodily fluids, or contaminated materials.
UKHSA has implemented heightened awareness and testing in high-risk areas, particularly in urban centres like London, Manchester, and Brighton, where vaccines are prioritised for those most at risk. Hopkins said: “We have an active plan of management.” This includes isolation and offering vaccines to close contacts, especially those at higher risk.
This Clade Ib strain has circulated in the Democratic Republic of Congo (DRC) and other countries, with over 600 reported deaths. The World Health Organization (WHO) declared a public health emergency due to its rapid spread. UKHSA is treating Clade Ib as a high consequence infectious disease and will adapt its response as more data emerges.
Health and Social Care Secretary Wes Streeting said: “We are working with UKHSA and the NHS to protect the public and prevent transmission.” Additional vaccines are also being procured as part of the UK’s proactive response.
